Оценка эффективности препарата трометамола композитума в комплексном лечении больных уратным уролитиазом

Urate urolithiasis: efficacy of combined treatment with trometamol compositum

Contact dissolution of urate concrements was assessed in a direct action of the drug trometamol compositum on a concrement in combination with modern low-invasive technologies. A total of 67 patients with urate urolithiasis were divided into two groups: 44 patients of group 1 have undergone contact litholysis, 23 patients of group 2 have undergone extracorporeal shock-wave lithotripsy followed by contact litholysis. Dissolution was made with the drug trometamol compositum (Berlin-Chemie, Germany) delivered antegradely through nephrostomic drainage made previously. Other important components of litholysis consisted in low-intensive laser radiation and prophylactic antibacterial therapy. Positive results were achieved in all the patients. Mean litholysis duration was 4.8 + 1.8 days in group 1 and 1.09 ± 0.29 days in group 2. Thus, high efficacy of the method is demonstrated.